We are Dedicated to
Biopharmaceutical
Research & Advancement

What We Do
Generex Biotechnology Corp., is a biopharmaceutical company that is actively involved in discovery, research, development, and financing of new compounds, therapies, diagnostics, delivery systems, and medical technologies.
News
  1. Generex Announces Reverse Stock Split
    March 14, 2017
    MIRAMAR, Florida & TORONTO, Canada, March 14, 2017 (BUSINESS WIRE) – Generex Biotechnology Corporation (OTCPink:GNBT) today announced a reverse stock split of its shares of common stock at a ratio of 1-for-1000. As of the open of the market on March 14, 2017, the Company’s common stock will begin trading on a split-adjusted basis.
    READ MORE
  2. Generex Announces $115M Convertible Preferred Stock Financing; First Tranche Satisfies Emmaus Deposit
    March 29, 2017
    MIRAMAR, Fla.--(BUSINESS WIRE)--Generex Biotechnology Corporation (OTC Pink:GNBTD) today announced that it has entered into a securities purchase agreement with an institutional investor pursuant to which such investor has agreed to purchase in a private placement (the “Private Placement”) in multiple tranches 109,000 shares of the Company’s newly designed Series H Convertible Preferred Stock (the “Series H CPS”) and 6,000 shares of the Company’s newly designed Series I Convertible Preferred Stock (the “Series I CPS”) (together, the “Preferred Stock”) for an aggregate purchase price of $115,000,000 ($1,000 per share of Preferred Stock). The Preferred Stock is convertible into shares of the Company’s common stock at a conversion price of $2.50 per share (subject to adjustment under certain circumstances).
    READ MORE
  3. Generex Announces Featured Presentation of Cancer Immunotherapy Developed by Subsidiary at OPT Boston
    March 27, 2017
    MIRAMAR, FL--(BUSINESS WIRE)--Generex Biotechnology Corporation (OTC Pink:GNBTD) today announced that Dr. Eric von Hofe, Ph.D., President of the Company’s wholly-owned immuno-therapeutics subsidiary, Antigen Express, Inc. (www.antigenexpress.com), will be a featured speaker at the Cambridge Healthtech Institute’s second annual Oligonucleotide & Peptide Therapeutics conference (OPT Boston) (www.optcongress.com) being held in Cambridge, MA March 27 – 29, 2017.
    READ MORE
  4. Generex Provides Access Information for Investor Conference Call Scheduled for February 22, 2017
    February 21, 2017
    MIRAMAR, Florida, February 21, 2017 (BUSINESS WIRE) -- Generex Biotechnology Corporation (OTCPink:GNBT) today announced the following access information for its investor conference call, to be hosted by Joseph Moscato, Company President & Chief Executive Officer, and his management team, tomorrow, Wednesday, February 22, 2017, at 10 am. Eastern time:
    READ MORE